-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
US FDA names agency critic Vinay Prasad as top vaccine official
-
RBC Capital on Moderna (MRNA): 'Next Few Months Key'
-
Moderna (MRNA) PT Lowered to $75 at RBC Capital
-
Midday movers: Apple, Nvidia, Intel, Coinbase and Moderna fall
-
RBC Capital Downgrades Moderna (MRNA) to Sector Perform
-
Moderna (MRNA) PT Raised to $160 at RBC Capital
-
Moderna (MRNA) PT Raised to $135 at RBC Capital
-
Today's most important initiations
-
Moderna (MRNA) started at Outperform as 'Covid Cliff' near-term impact well appreciated
-
RBC Capital Starts Moderna (MRNA) at Outperform, 'We Are Cancer Vaccine Believers'
-
Joe Biden's Super Tuesday success could help calm coronavirus-rocked market
-
Notable Analyst Rating Changes 7/29: MCK, CPB, COH, ROK, MEE Upgraded; MS, MGM, AFL, WDC, PERY, LRY Downgraded

